

## **Article 25fa pilot End User Agreement**

This publication is distributed under the terms of Article 25fa of the Dutch Copyright Act (Auteurswet) with explicit consent by the author. Dutch law entitles the maker of a short scientific work funded either wholly or partially by Dutch public funds to make that work publicly available for no consideration following a reasonable period of time after the work was first published, provided that clear reference is made to the source of the first publication of the work.

This publication is distributed under The Association of Universities in the Netherlands (VSNU) 'Article 25fa implementation' pilot project. In this pilot research outputs of researchers employed by Dutch Universities that comply with the legal requirements of Article 25fa of the Dutch Copyright Act are distributed online and free of cost or other barriers in institutional repositories. Research outputs are distributed six months after their first online publication in the original published version and with proper attribution to the source of the original publication.

You are permitted to download and use the publication for personal purposes. All rights remain with the author(s) and/or copyrights owner(s) of this work. Any use of the publication other than authorised under this licence or copyright law is prohibited.

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please contact the Library through email: [copyright@ubn.ru.nl](mailto:copyright@ubn.ru.nl), or send a letter to:

University Library  
Radboud University  
Copyright Information Point  
PO Box 9100  
6500 HA Nijmegen

You will be contacted as soon as possible.

# Start of insulin therapy in patients with type 2 diabetes mellitus promotes the influx of macrophages into subcutaneous adipose tissue

H. J. Jansen · R. Stienstra · J. A. van Diepen · A. Hijmans ·  
J. A. van der Laak · G. M. M. Vervoort · C. J. Tack

Received: 26 January 2013 / Accepted: 24 June 2013 / Published online: 25 September 2013  
© Springer-Verlag Berlin Heidelberg 2013

## Abstract

**Aims/hypothesis** Insulin therapy in patients with type 2 diabetes mellitus is accompanied by weight gain characterised by an increase in abdominal fat mass. The expansion of adipose tissue mass is generally paralleled by profound morphological and inflammatory changes. We hypothesised that the insulin-associated increase in fat mass would also result in changes in the morphology of human subcutaneous adipose tissue and in increased inflammation, especially when weight gain was excessive.

**Methods** We investigated the effects of weight gain on adipocyte size, macrophage influx, and mRNA expression and protein levels of key inflammatory markers within the adipose tissue in patients with type 2 diabetes mellitus before and 6 months after starting insulin therapy.

**Results** As expected, insulin therapy significantly increased body weight. At the level of the subcutaneous adipose tissue, insulin treatment led to an influx of macrophages. When comparing patients gaining no or little weight with patients gaining >4% body weight after 6 months of insulin therapy, both subgroups displayed an increase in macrophage influx. However, individuals who had gained weight had higher protein levels of monocyte chemoattractant protein-1,

TNF- $\alpha$  and IL-1 $\beta$  after 6 months of insulin therapy compared with those who had not gained weight.

**Conclusions/interpretation** We conclude that insulin therapy in patients with type 2 diabetes mellitus improved glycaemic control but also induced body weight gain and an influx of macrophages into the subcutaneous adipose tissue. In patients characterised by a pronounced insulin-associated weight gain, the influx of macrophages into the adipose tissue was accompanied by a more pronounced inflammatory status.

**Trial registration** ClinicalTrials.gov: NCT00781495.

**Funding** The study was funded by European Foundation for the Study of Diabetes and the Dutch Diabetes Research Foundation.

**Keywords** Insulin therapy · Macrophages · Type 2 diabetes mellitus · Weight gain

## Abbreviations

CLS	Crown-like structure
MCP-1	Monocyte chemoattractant protein-1
MMP	Matrix metalloproteinase
PAI-1	Plasminogen activator inhibitor-1
qPCR	Quantitative PCR

**Electronic supplementary material** The online version of this article (doi:10.1007/s00125-013-3018-6) contains peer-reviewed but unedited supplementary material, which is available to authorised users.

H. J. Jansen (✉) · R. Stienstra · J. A. van Diepen · A. Hijmans ·  
G. M. M. Vervoort · C. J. Tack  
Department of Internal Medicine 463, Radboud University Nijmegen  
Medical Centre, PO Box 9101, 6500 HB Nijmegen, the Netherlands  
e-mail: H.Jansen@jzbz.nl

J. A. van der Laak  
Department of Pathology, Radboud University Nijmegen Medical  
Centre, Nijmegen, the Netherlands

## Introduction

Insulin therapy is frequently needed to achieve adequate glycaemic control in patients with type 2 diabetes mellitus yet often results in undesirable weight gain. Although values differ and studies are generally of limited duration, the estimated weight gain during the first year of insulin therapy ranges from approximately 2 to 6 kg [1]. This weight gain is paralleled by an increase in abdominal fat mass [1].

When obesity develops, the adipose tissue undergoes distinct morphological changes including adipocyte enlargement and macrophage influx [2]. In adipose tissue in obese individuals, macrophages may be arranged in so-called crown-like structures (CLSs) that surround dysfunctional or dying adipocytes [3] and are characterised as having a more pro-inflammatory nature than individual macrophages dispersed throughout the adipose tissue [4].

In general, these changes lead to a more pronounced inflammatory status of the adipose tissue that is reflected by an increased secretion of pro-inflammatory mediators by the adipose tissue and a reduction in secretion of the insulin-sensitising protein adiponectin [5]. The enhanced inflammatory status of the adipose tissue is thought to contribute to the development of systemic insulin resistance that may eventually evolve into type 2 diabetes. Although inflammatory changes in the adipose tissue are well described in individuals who develop obesity, it remains unknown whether similar changes in the morphological and inflammatory characteristics of subcutaneous adipose tissue also occur in patients with type 2 diabetes who start insulin therapy and subsequently gain weight.

An emerging body of evidence suggests that insulin suppresses the inflammatory process, not only through preventing hyperglycemia, but also by modulating key inflammatory molecules. Studies that have examined the effects of (intensive) insulin therapy on immune function and inflammatory factors have shown that the levels of systemic pro-inflammatory cytokines decrease after administration of insulin [6, 7].

One may hypothesise that the anti-inflammatory effects of insulin at the systemic level may be counteracted by the pro-inflammatory changes associated with an increased fat mass. This may be particularly true in those who gain most weight. To test this hypothesis, we investigated changes in the morphological characteristics of adipose tissue, macrophage influx, and mRNA expression and protein levels of key inflammatory markers within the adipose tissue in patients with type 2 diabetes mellitus before and 6 months after the start of insulin therapy. We also assessed whether potential changes were related to excessive weight gain.

## Methods

**Patients** This study was part of a large prospective, multicentre, observational study aimed at identifying the determinants of insulin-induced weight gain in type 2 diabetes (abstract EASD no. 942; 2012, Berlin; ClinicalTrials.gov NCT00781495,  $n=65$  patients). In short, the patients recruited were those with type 2 diabetes who failed therapy with oral glucose-lowering agents and/or dietary modifications and were started on insulin therapy. All patients were treated

according to local guidelines. The majority of the patients used an oral glucose-lowering agent (metformin and/or sulfonylurea derivative) throughout the study.

To determine the impact of a high weight gain on the inflammatory status of the adipose tissue, we divided the study population into two subgroups of patients: ‘gainers’ (patients displaying >4% weight gain after 6 months of insulin therapy;  $n=10$ ) and ‘non-gainers’ (patients with a weight gain  $\leq 4\%$ ;  $n=33$ ) [1, 8]. Furthermore, we included a matched non-diabetic obese subgroup (BMI 27–43 kg/m<sup>2</sup>, age 40–70 years;  $n=42$ ) in order to compare the morphological characteristics of adipose tissue, macrophage influx and protein levels of key inflammatory markers. Exclusion criteria were earlier use of insulin, other types of diabetes, including steroid-induced diabetes, evidence of psychiatric, renal, cardiovascular, liver or other diseases and use of medication (prednisone) that might influence the study results.

Before and after 6 months of insulin treatment, BMI, waist circumference and skinfold thickness were measured. Body composition was assessed using formulas described by Jackson and Pollock [9, 10]. At baseline (i.e. prior to insulin treatment) and after 6 months of insulin therapy, subcutaneous adipose tissue biopsies were obtained under local anaesthesia from needle biopsies performed 6–10 cm lateral to the umbilicus after an overnight fast. The same measurements were performed in the non-diabetic obese participants.

The study protocol was approved by the local ethical committee. All study participants provided written informed consent.

**Biochemical analyses** Plasma glucose concentration and HbA<sub>1c</sub> level were measured by standard laboratory methods. Furthermore, we measured plasma adiponectin, leptin, IL-8 and high sensitive C-reactive protein (R&D systems, Minneapolis, MN, USA).

**Subcutaneous adipose tissue morphology and immunohistochemistry** The morphometry of individual fat cells was assessed using digital image analyses as previously described [11]. For each participant, the adipocyte cell diameters of all the fat cells in five to ten microscopic fields of view were counted and measured. On average, approximately 700 fat cells (range 150–1,500) were measured per specimen. The distribution of adipocyte cell size was expressed as the ratio of small ( $\leq 50$   $\mu\text{m}$ ) to large ( $\geq 100$   $\mu\text{m}$ ) adipocytes [12]. For detection of macrophages, adipose tissue sections were incubated with a CD68-monoclonal antibody (Clone EBM11, Dako, Denmark). The percentage of macrophages was expressed as the total number of CD68-positive cells divided by the total number of adipocytes counted in ten random microscopic  $\times 100$  fields of view. A CLS was defined as an adipocyte surrounded by at least three macrophages [13].

**RNA isolation and qPCR analysis** Total RNA was extracted from subcutaneous adipose tissue as previously [14]. cDNA synthesis was performed using iScript (Bio-Rad Laboratories, Hercules, CA, USA). Gene expression was determined by real-time PCR analysis (Applied Biosystems, Warrington, Cheshire, UK). Gene expression results were normalised to  $\beta$ -2-microglobulin ( $\beta$ 2M) levels. To compare gainers and non-gainers, results from a maximum of ten individuals are presented for gainers and from 33 individuals who were part of the non-gainers group. The genes and primer sequences used in this study are listed in ESM Table 1.

**Luminex analysis** Protein levels within the adipose tissue biopsies were measured by Luminex fluorescent bead human cytokine immunoassays in line with the manufacturer's instructions (Milliplex MAP; Millipore, Billerica, MA, USA). Briefly, adipose tissue lysates were prepared using the Milliplex map lysis buffer (Millipore), and protein concentrations of IL-1 $\beta$ , IL-6, IL-8, TNF- $\alpha$ , leptin (LEPTIN), adiponectin (ADIPONECTIN), monocyte chemoattractant protein-1 (MCP-1), resistin (RESISTIN) and plasminogen activator inhibitor-1 (PAI-1) were determined. To measure the protein levels in adipose tissue using Luminex beads, 30% lysates of each sample (300 mg of adipose tissue in 1,000  $\mu$ l of lysis buffer) were prepared. Protein concentrations of the various samples were measured using a bicinchoninic assay. Equal amounts of protein (28.2  $\mu$ g) were analysed using a Bio-Plex system (Bio-Rad). In comparing gainers and non-gainers [1, 8], results from a maximum of ten individuals are presented for gainers and from 33 individuals who were part of the non-gainers group. A maximum of 37 non-diabetic obese participants are presented. Missing values were due to technical issues or measurements below the detection level of the Luminex assays.

**Statistical analyses** Descriptive patient characteristics and other variables are displayed as mean  $\pm$  SD unless otherwise indicated. Differences after insulin treatment were studied using the Student's paired *t* test, Wilcoxon signed-rank test and Mann–Whitney *U* test as appropriate. The  $\chi^2$ -square test was used to compare dichotomous variables. All calculations were performed using SPSS 20.0 for Windows (SPSS, Chicago, IL, USA). Two-tailed *p* values <0.05 were considered significant in all statistical comparisons.

## Results

**Start of insulin therapy** A total of 43 patients with type 2 diabetes who started insulin therapy underwent paired adipose tissue biopsies. The baseline anthropometric and laboratory characteristics of the study group are shown in Table 1. After

6 months, 25 patients (58%) used basal insulin only, four patients (9%) were using biphasic insulin and 14 patients (33%) were on basal and bolus insulin. At 6 months, patients were using  $0.37 \pm 0.24$  U insulin/kg body weight. Fifty-eight per cent of the patients were injecting their insulin into the thigh area, whereas 42% were injecting insulin into the abdomen. Of those patients injecting insulin into the thigh area at the initiation of insulin therapy ( $n=26$ ; 61%), 13 patients (30%) were still injecting insulin only into the thigh area at 6 months. Insulin treatment increased body weight from  $88.1 \pm 18.1$  to  $89.3 \pm 18.0$  kg (range  $-4.5$  to  $7.4$  kg;  $p < 0.05$ ). In addition, BMI, waist circumference and calculated body fat mass increased significantly. HbA<sub>1c</sub> levels dropped from  $8.7 \pm 1.1\%$  ( $72 \pm 12$  mmol/mol) to  $7.4 \pm 1.0\%$  ( $57 \pm 11$  mmol/mol) ( $p < 0.05$ ).

**Subcutaneous adipose tissue samples** Figure 1a–b shows a histological overview of the adipose tissue sections before and after the start of insulin therapy. Insulin therapy had no effect on adipocyte cell diameter ( $69.5 \pm 7.7$   $\mu$ m and  $70.7 \pm 6.9$   $\mu$ m at baseline and 6 months, respectively;  $p = 0.43$ ). Similarly,

**Table 1** Demographic and clinical characteristics of patients with type 2 diabetes mellitus


Variable	Baseline	6 months
<i>n</i>	43	43
Age (years)	61 $\pm$ 9	–
Sex (m/f)	25/18	–
Duration of diabetes (years)	10 $\pm$ 9	–
Weight loss prior start insulin therapy (kg) <sup>a</sup>	1.4 $\pm$ 2.7	–
BMI (kg/m <sup>2</sup> )	29.8 $\pm$ 5.2	30.3 $\pm$ 5.1*
Waist circumference (cm)	106 $\pm$ 14	107 $\pm$ 13 <sup>†</sup>
Lean weight (kg)	70 $\pm$ 14	68 $\pm$ 9*
Fat weight (kg)	19 $\pm$ 9	21 $\pm$ 9*
Body fat (%)	20 $\pm$ 7	23 $\pm$ 7
Systolic blood pressure (mmHg)	143 $\pm$ 20	138 $\pm$ 18
Diastolic blood pressure (mmHg)	79 $\pm$ 8	79 $\pm$ 8
Fasting glucose (mmol/l)	11.6 $\pm$ 3.0	–
HbA <sub>1c</sub> (%)	8.7 $\pm$ 1.1	7.4 $\pm$ 1.0*
HbA <sub>1c</sub> (mmol/mol)	72 $\pm$ 12	57 $\pm$ 11
Alcohol use ( <i>n</i> )	13	–
Smoking ( <i>n</i> )	3	–
Concomitant use of oral glucose-lowering agents ( <i>n</i> )		
MET only	6	18*
SU only	3	3
MET + SU	34	22*

Data are presented as mean  $\pm$  SD

<sup>a</sup> Weight loss in the 12 months prior to the initiation of insulin

\* $p < 0.05$ , <sup>†</sup> $p = 0.06$

MET, metformin; SU, sulfonylurea derivatives; –, not applicable




**Fig. 1** Histological overview of subcutaneous adipose tissue before (a) and after 6 months of insulin therapy (b) in a patient with type 2 diabetes mellitus. This patient gained 3.7 kg after 6 months of insulin treatment, without a change in average adipocyte cell size (56.6  $\mu\text{m}$ ). Sections were stained with haematoxylin and eosin. Magnification  $\times 10$ . (c) The graph shows the frequency (percentage) distribution of absolute adipocyte cell size ( $\mu\text{m}$ ) at baseline (solid line) and after 6 months of insulin treatment (dashed line). Bin width 2  $\mu\text{m}$ .  $n=43$  individuals for both time points

insulin did not affect the size distribution of the adipocytes (Fig. 1c) or the percentage of small adipocytes (18.3 $\pm$ 10.1% at baseline vs 17.7 $\pm$ 10.6% after insulin;  $p=0.82$ ) or large adipocytes (9.7 $\pm$ 8.3 vs 9.8 $\pm$ 8.1%;  $p=0.95$ ). The adipocyte cell size was similar compared with that of non-diabetic obese individuals (Electronic supplementary material [ESM] Table 2 and ESM Fig. 1a).

**Macrophage influx** The influx of CD68-positive cells per adipocyte was higher in patients with type 2 diabetes mellitus compared with non-diabetic participants (ESM Fig. 1b).


Strikingly, insulin therapy increased macrophage influx even further, as shown by the number of CD68-positive cells per adipocyte (0.07 $\pm$ 0.06 vs 0.16 $\pm$ 0.09;  $p<0.001$ ; Fig. 2a–f and ESM Fig. 1b). Males and females displayed a similar increase in the influx of CD68-positive cells per adipocyte (males, 0.1 $\pm$ 0.1; females, 0.1 $\pm$ 0.1;  $p=0.38$ ). The increase in CD68-positive cells before and after insulin treatment was not correlated with the degree of weight gain in our population, suggesting that insulin therapy, independently of weight gain, increases the number of macrophages within the adipose tissue (see below). Noticeably, the number of CLSs present in the subcutaneous adipose tissue did not change significantly from before to after 6 months of insulin therapy (30% vs 37%;  $p=0.65$ ). The degree of macrophage influx was independent of the insulin injection site.



**Fig. 2** Representative sections of subcutaneous adipose tissue morphology and CD68-immunohistochemical staining before and after 6 months of insulin therapy. No influx of macrophages before insulin therapy (a) and after 6 months of insulin therapy (b) was seen in a patient with 3.7 kg of weight gain. A moderate influx of macrophages (arrows) before insulin treatment (c) and a significant increase in macrophage influx as well as a CLS (star) after 6 months of insulin therapy (d) were seen in a patient with 4.5 kg of weight gain. All sections were counterstained with haematoxylin (blue). Magnification  $\times 10$ . (e) Quantification of macrophage influx showing a significant increase in the number of CD68-positive cells after 6 months of insulin therapy. The horizontal lines represent the means.  $n=43$  individuals for both time points.  $*p<0.001$ . (f) Frequency (percentage) distribution of the influx of macrophages (CD68-positive cells per adipocyte) at baseline (solid line) and after 6 months of insulin treatment (dashed line). Bin width 0.04 CD68 $^{+}$  cells/adipocyte.  $n=43$  individuals for both time points

**Gene expression values in adipose tissue** The degree of influx of macrophages into the adipose tissue, as measured by immunohistochemical staining, is mirrored by a similar trend in the mRNA expression of the macrophage-specific markers *F4/80* and *CD38* (ESM Fig. 2).

Since an enhancement in macrophage influx into adipose tissue is known to increase the inflammatory state of the adipose tissue, we set out to measure the changes in mRNA levels of key adipocytokines within adipose tissue biopsies. After 6 months of insulin treatment, mRNA expression levels of glucose transporter type 4 (*SLC2A4*) and *IL6* were significantly increased, whereas the gene expression levels of peroxisome proliferator receptor gamma (*PPARG*), adiponectin (*ADIPOQ*), monocyte chemoattractant protein-1 (*CCL2*) and *IL8* were not changed significantly (Fig. 3a). The influx of



**Fig. 3** (a) Changes in the relative gene expression levels of adipose tissue function (*SLC2A4*, *PPARG*, *ADIPOQ*) and pro-inflammatory related (*CCL2*, *IL6* and *IL8*) genes. Left axis: *IL6*, *SLC2A4*; right axis: *PPARG*, *ADIPOQ*, *CCL2*, *IL8*. The lowest gene expression level in quantitative (q)PCR analysis at baseline was set at 1. The mean fold changes of *SLC2A4*, *PPARG*, *ADIPOQ*, *CCL2*, *IL6* and *IL8* were 1.37, 1.27, 1.03, 1.14, 1.55 and 1.00, respectively. 0, at baseline; 6, after 6 months of insulin treatment. The horizontal lines represent the means.  $n=37$  individuals per gene per time point, except for *IL6* ( $n=35$

individuals for both time points).  $*p<0.05$ . (b) Protein levels measured for the adipose tissue displaying adipose tissue function (leptin, resistin) and (c) pro-inflammatory related protein levels (left axis: MCP-1, IL-1 $\beta$ , IL-6, IL-8, TNF- $\alpha$ ; right axis: PAI-1). 0, at baseline; 6, after 6 months of insulin treatment. The horizontal lines represent the means. The mean fold changes of leptin, resistin, MCP-1, IL-1 $\beta$ , IL-6, IL-8, TNF- $\alpha$  and PAI-1 were 1.16, 1.05, 0.93, 0.82, 1.18, 0.99, 1.08 and 1.09, respectively.  $n=36$  individuals per protein per time point

macrophages into the adipose tissue may also aid remodelling processes that may occur to accommodate the expansion of the adipose tissue mass upon insulin-associated weight gain. Hence, we measured the expression levels of several genes related to adipose tissue remodelling. As shown in ESM Fig. 3, none of the gene expressions had changed significantly after 6 months of insulin therapy.

**Protein levels in adipose tissue** To more extensively characterise the inflammatory status of the adipose tissue before and after 6 months of insulin therapy, the protein levels of various inflammatory adipokines including IL-1 $\beta$ , IL-6, IL-8, active PAI-1, TNF- $\alpha$  and MCP-1 were determined in adipose tissue. Patients with type 2 diabetes have higher protein levels of IL-8, MCP-1, PAI-1 and resistin within the subcutaneous adipose tissue compared with non-diabetic obese individuals (ESM Fig. 4). Noticeably, adipocyte size was similar between the two study populations, whereas the influx of macrophages was enhanced in patients with type 2 diabetes.

As shown in Fig. 3b, there was no significant change in protein levels of leptin and resistin after 6 months of insulin treatment. In addition, adipose tissue levels of the various pro-

inflammatory mediators in adipose tissue after 6 months of insulin treatment were unchanged (Fig. 3c).

**Circulating hormones and inflammatory markers** It has been unknown whether insulin and weight gain have an impact on circulating plasma markers. Therefore, we collected plasma at baseline and after 12 months of insulin treatment (as part of the original study). Circulating leptin levels significantly increased after insulin therapy. The other circulating markers did not change significantly (ESM Fig. 5a).

**Gainers versus non-gainers** It is a well-known fact that weight gain favours enlargement of the adipocytes and a shift towards a more pro-inflammatory status of the adipose tissue [5]. Although 6 months of insulin therapy significantly enhanced body weight within our study population, a pronounced interindividual variation was observed. Therefore, we divided the group into two subgroups of patients, ‘gainers’ (patients displaying >4% weight gain after 6 months of insulin therapy;  $n=10$ ) and ‘non-gainers’ (patients with weight gain  $\leq 4\%$ ;  $n=33$ ), to compare the effects of high weight gain with

those of no or limited weight gain on the inflammatory status of the adipose tissue.

The baseline characteristics of non-gainers and gainers are presented in Table 2. At baseline, the body weight of the gainers was significantly less than that of the non-gainers. The mean weight gain for gainers was  $4.7\pm 1.5$  kg, compared with  $0.09\pm 2.3$  kg ( $p<0.001$ ) for non-gainers, and the insulin dose at 6 months was 45 IU ( $0.57\pm 0.37$  U insulin/kg body weight) in gainers and 29 IU ( $0.31\pm 0.15$  U insulin/kg body weight) in non-gainers (both variables  $p<0.05$ ). The change in glycaemic control (HbA<sub>1c</sub>) was  $-1.79\%$  ( $-2$  mmol/mol) vs  $-1.04\%$  ( $-1.0$  mmol/mol) in gainers and non-gainers, respectively ( $p=0.11$ ). There was no significant increase in adipocyte cell size in the two groups ( $65.8\pm 7.0$  to  $67.5\pm 6.9$   $\mu\text{m}$  vs  $70.6\pm 7.6$  to  $71.6\pm 6.7$   $\mu\text{m}$ , in gainers vs non-gainers, respectively; both  $p=0.50$  for the difference in adipocyte cell size within the subgroup). Interestingly, the number of macrophages, quantified by the number of CD68-positive cells, in the adipose tissue was significantly raised in both groups after 6 months of insulin therapy (Fig. 4a), indicating that the influx of macrophages was independent of weight gain.

**Table 2** Baseline demographic and clinical characteristics comparing non-gainers and gainers

Variable	Non-gainers	Gainers
<i>n</i>	33	10
Age (years)	61 $\pm$ 10	64 $\pm$ 12
Duration of diabetes (years)	9 $\pm$ 6	14 $\pm$ 14
Weight loss prior start insulin therapy (kg) <sup>a</sup>	1.1 $\pm$ 2.2	2.2 $\pm$ 4.0
BMI (kg/m <sup>2</sup> )	30.9 $\pm$ 5.4	26.3 $\pm$ 2.4*
Waist circumference (cm)	109 $\pm$ 13	99 $\pm$ 12*
Lean weight (kg)	72 $\pm$ 14	64 $\pm$ 10*
Fat weight (kg)	20 $\pm$ 9	13 $\pm$ 5*
Body fat (%)	22 $\pm$ 7	17 $\pm$ 5*
Systolic blood pressure (mmHg)	115 $\pm$ 21	138 $\pm$ 15
Diastolic blood pressure (mmHg)	80 $\pm$ 11	78 $\pm$ 5
Fasting glucose (mmol/l)	11.3 $\pm$ 2.7	12.5 $\pm$ 3.9
HbA <sub>1c</sub> (%)/(mmol/mol)	8.6 $\pm$ 0.9/ (70 $\pm$ 10)	9.0 $\pm$ 1.4/ (75 $\pm$ 15)
Alcohol use ( <i>n</i> )	6	7
Smoking ( <i>n</i> )	4	2
Concomitant use of oral glucose-lowering agents ( <i>n</i> )		
MET	4	3
SU	1	2
MET + SU	28	5

Data are presented as mean  $\pm$  SD

<sup>a</sup>Weight loss in the 12 months prior to the initiation of insulin

\* $p<0.05$

MET, metformin; SU, sulfonylurea derivatives

No significant changes in gene expression levels were observed when comparing gainers and non-gainers (Fig. 4b). However, protein levels within the adipose tissue displayed significant differences between gainers and non-gainers. Protein levels of MCP-1, TNF- $\alpha$  and IL-1 $\beta$  significantly increased in gainers compared with non-gainers (Fig. 4d), suggesting that pronounced insulin-associated weight gain might promote a more pro-inflammatory status of the adipose tissue that is independent of the absolute number of macrophages. When comparing circulating hormones and inflammatory markers in non-gainers vs gainers, we observed in gainers a significantly larger decrease in adiponectin levels and a significant larger increase in leptin levels (ESM Fig. 5b).


## Discussion

In the present study, we demonstrated that 6 months of insulin therapy per se leads to an increase in the influx of macrophages into the subcutaneous adipose tissue in patients with type 2 diabetes mellitus, an effect that is independent of the level of weight gain. However, the subgroup that gained a more pronounced ( $>4\%$ ) amount of body weight showed an increased inflammatory status of the adipose tissue as reflected by an increase in the levels of pro-inflammatory cytokines (MCP-1, TNF- $\alpha$  and IL-1 $\beta$ ) in the adipose tissue.

The mean insulin-associated weight gain in this study equalled 1.2 kg after 6 months, with a considerable interindividual variation. Glycaemic control significantly improved but HbA<sub>1c</sub> levels at 6 months of insulin therapy were suboptimal. These changes in body weight and glycaemic control reflect real-life clinical practice outcomes.

Insulin-associated weight gain leads to an increase in fat mass. Interestingly, despite a lower total adipose tissue mass in patients diagnosed with diabetes compared with obese non-diabetic subjects (19 kg vs 22 kg, respectively), the adipocyte cell size in the subcutaneous depot tends to be higher in the presence of type 2 diabetes (70  $\mu\text{m}$  vs 67  $\mu\text{m}$ , respectively). Hence, this observation suggests that the presence of type 2 diabetes inflicts adipocyte hypertrophy possibly via insufficient adipocyte differentiation, and thereby limits proper storage in the subcutaneous fat depot. Although the development of obesity and weight gain induces an enlargement of subcutaneous adipocyte cells [2], no significant increase in adipocyte cell size after 6 months of insulin treatment was observed within our study population. This may be explained by the relatively moderate weight gain observed after 6 months of insulin therapy, which was probably too small to affect adipocyte cell size. It may also be envisioned that insulin induces the differentiation of new adipocytes [15] and thereby increases storage capacity without any change in adipocyte size.

Changes in the inflammatory nature of the adipose tissue, including the influx of macrophages and altered levels of



**Fig. 4** (a) A change in influx of CD68-positive cells into the subcutaneous adipose tissue after 6 months of insulin therapy comparing non-gainers (white bars;  $\leq 4\%$  weight gain) and gainers (black bars;  $>4\%$  weight gain). Data are presented as mean  $\pm$  SEM.  $n=33$  non-gainers vs  $n=10$  gainers for both time points.  $*p<0.05$ . (b) Changes in the relative gene expression levels of adipose tissue function (*SLC2A4*, *PPARG* and *ADIPOQ*) and inflammation (*CCL2*, *IL6* and *IL8*) showing no significant change after 6 months of insulin therapy in patients displaying no or minimal weight gain ( $\leq 4\%$ ; NG) compared with a pronounced weight gain ( $>4\%$ ; G). Left axis: *IL6*; right axis, *SLC2A4*, *PPARG*, *ADIPOQ*, *CCL2* and *IL8*. The lowest gene expression level in qPCR analysis at baseline was set at 1. The horizontal lines represent the means.  $n=28$

values per gene/fold change for non-gainers and  $n=9$  for gainers, except for *IL6* ( $n=27$  individuals for gene expression levels in non-gainers and  $n=8$  individuals for gainers). (c) Change in adipose tissue function (leptin and resistin) and (d) pro-inflammatory-related protein levels (left axis: MCP-1, IL-1 $\beta$ , IL-6, IL-8, TNF- $\alpha$  and PAI-1) after 6 months of insulin therapy comparing patients displaying no or minimal weight gain ( $\leq 4\%$ ; NG) with patients showing a pronounced weight gain ( $>4\%$ ; G). Left axis, MCP-1; right axis, IL-1 $\beta$ , IL-6, IL-8, TNF- $\alpha$ , PAI-1. The horizontal lines represent the means.  $n=27$  individuals for protein levels measured in non-gainers versus  $n=9$  individuals for proteins measured in gainers, except for IL-1 $\beta$  ( $n=8$  for gainers).  $*p<0.05$ ,  $\dagger p=0.09$

adipocytokines, rather than changes in adipocyte morphology are more important consequences of insulin-associated weight gain. Indeed, 6 months of insulin therapy led to a significant increase in the number of macrophages in the subcutaneous adipose tissue. The degree of macrophage influx was, however, independent of the level of weight gain, and the enhanced number of macrophages present in the adipose tissue was not accompanied by an upsurge in inflammatory status as the levels of various inflammatory adipokines within the adipose tissue were unaltered.

These results suggest that the influx of macrophages upon insulin therapy serves a different purpose. A potential

explanation for this phenomenon may involve the tissue remodelling function of macrophages [16, 17]. Macrophages are not only capable of mediating inflammatory responses, but also aid remodelling processes that may occur to accommodate the expansion of adipose tissue mass upon insulin-induced weight gain. However, the expression levels of genes related to adipose tissue remodelling, including those for PAI-1, TIMP-1 (tissue metalloproteinase inhibitor 1), matrix metalloproteinase-2 (MMP-2), MMP-3 and MMP-11 [18–20], were not significantly changed. Although weight gain might lead to an upregulation of the genes related to angiogenesis and extracellular matrix remodelling [21], our



results suggest that insulin-induced weight gain exerts different effects on extracellular matrix remodelling.

Interestingly, lipolysis has been shown to promote the influx of macrophages into adipose tissue that function to prevent excessive spill-over of non-esterified fatty acids into the circulation [22]. As insulin inhibits lipolysis, the influx of macrophages upon initiation of insulin therapy appears to be somewhat counterintuitive. However, the insulin-mediated influx probably occurs independently of lipolysis and reflects the tissue-remodelling action of the macrophages. Whether insulin directly affects the influx of macrophages into adipose tissue or exerts its effects via indirect mechanisms that ultimately lead to an enhanced number of adipose tissue macrophages remains to be determined.

Finally, the influx of macrophages into the adipose tissue may be a direct result of injecting insulin into the abdomen. However, we did not observe a difference in the influx of macrophages into the adipose tissue between patients injecting insulin into the thigh area compared with those who injected insulin into the abdomen (data not shown), rendering any direct effects of insulin or its injection site on the influx of macrophages unlikely.

Although no effects on inflammation were observed in our total study population, a classification of our patients based on the degree of weight gain did reveal interesting differences. Whereas both non-gainers and gainers demonstrated a significant increase in macrophage influx into the adipose tissue, the gainers displayed an increase in pro-inflammatory cytokine production (MCP-1, IL-1 $\beta$  and TNF- $\alpha$ ) after 6 months of insulin treatment compared with non-gainers. These results imply that, in gainers, the influx of macrophages is paralleled by an enhancement of the inflammatory status of the adipose tissue. As the total number of macrophages present after 6 months of treatment did not differ between the subgroups, it can be suggested that the phenotype of the macrophages is more pro-inflammatory, the adipocytes themselves are more inflamed, or other immune cells have infiltrated the adipose tissue in participants who gained over 4% of body weight. Although various reports have suggested that insulin suppresses inflammatory processes (at least systemically) [6, 7], more excessive weight gain after the start of insulin therapy may overrule any anti-inflammatory actions of insulin.

Even in the absence of weight gain, insulin will have a direct effect on adipocytes as well as indirect effects through, for example, altered levels of circulating nutrients and hormones. Interestingly, only serum leptin increased significantly after insulin treatment. It can be envisioned that the effects observed after the start of insulin therapy are primarily a result of the direct effects of insulin and not indirect consequences of a change in circulating factors. Remarkably, the change in the number of adipose tissue macrophages upon insulin therapy is not translated into a systemic enhancement of inflammatory status.

Our study has several limitations. First, the analyses were done using the subcutaneous fat tissue compartment and do not necessarily implicate similar changes in other fat compartments. However, most studies, including our own, have found that inflammatory changes in the visceral adipose tissue are mirrored by similar changes in subcutaneous adipose tissue [23]. In addition, the intake and energy expenditure of the patients studied was partly unknown and may have affected the degree of overweight and adipose tissue inflammation [24, 25].

The strength of our study includes the extensive phenotyping of over 40 participants and careful pair-wise analysis of subcutaneous adipose tissue morphology and inflammatory changes. In addition, the determination of protein levels in adipose tissue has, to our knowledge, not previously been applied and yields more valuable information concerning adipose tissue function than measurements of mRNA expression levels and circulating protein concentrations.

In conclusion, our results demonstrate that 6 months of insulin treatment lead to a significant influx of macrophages in patients with type 2 diabetes. This effect is independent of weight gain. However, pronounced insulin-associated weight gain (>4%), is paralleled by pro-inflammatory changes in the subcutaneous adipose tissue. Furthermore, gainers showed a higher increase in insulin dose compared with non-gainers, suggesting that a concomitant body weight gain and a shift towards a more pro-inflammatory profile of the adipose tissue might be associated with insulin resistance. The systemic anti-inflammatory effects of insulin (therapy) might be, at least partially, offset by the pro-inflammatory changes associated with an increased fat mass.

**Funding** Funding was received from the European Foundation for the Study of Diabetes and the Dutch Diabetes Research Foundation.

**Duality of interest** The authors declare that there is no duality of interest associated with this manuscript.

**Contribution statement** HJJ and RS researched the data and wrote the manuscript. GMMV and CJT reviewed and edited manuscript. JvD, JvdL and AH contributed to discussions and reviewed and edited the manuscript. All authors were responsible for the conception and design of the manuscript, drafting the article and revising it critically for important intellectual content. All authors approved the version to be published.

## References

1. Jansen HJ, Vervoort G, van der Graaf M, Tack CJ (2010) Pronounced weight gain in insulin-treated patients with type 2 diabetes mellitus is associated with an unfavourable cardiometabolic risk profile. *Neth J Med* 68:359–366
2. Farb MG, Bigornia S, Mott M et al (2011) Reduced adipose tissue inflammation represents an intermediate cardiometabolic phenotype in obesity. *J Am Coll Cardiol* 58:232–237

3. Sun K, Kusminski CM, Scherer PE (2011) Adipose tissue remodeling and obesity. *J Clin Invest* 121:2094–2101
4. Wentworth JM, Naselli G, Brown WA et al (2010) Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. *Diabetes* 59:1648–1656
5. Lumeng CN, Saltiel AR (2011) Inflammatory links between obesity and metabolic disease. *J Clin Invest* 121:2111–2117
6. Hasegawa A, Iwasaka H, Hagiwara S et al (2011) Anti-inflammatory effects of perioperative intensive insulin therapy during cardiac surgery with cardiopulmonary bypass. *Surg Today* 41:1385–1390
7. Hyun E, Ramachandran R, Hollenberg MD, Vergnolle N (2011) Mechanisms behind the anti-inflammatory actions of insulin. *Crit Rev Immunol* 31:307–340
8. St Jeor ST, Brunner RL, Harrington ME et al (1997) A classification system to evaluate weight maintainers, gainers, and losers. *J Am Diet Assoc* 97:481–488
9. Jackson AS, Pollock ML (1978) Generalized equations for predicting body density of men. *Br J Nutr* 40:497–504
10. Jackson AS, Pollock ML, Ward A (1980) Generalized equations for predicting body density of women. *Med Sci Sports Exerc* 12:175–181
11. Stienstra R, Duval C, Keshtkar S, van der Laak J, Kersten S, Muller M (2008) Peroxisome proliferator-activated receptor gamma activation promotes infiltration of alternatively activated macrophages into adipose tissue. *J Biol Chem* 283:22620–22627
12. McLaughlin T, Sherman A, Tsao P et al (2007) Enhanced proportion of small adipose cells in insulin-resistant vs insulin-sensitive obese individuals implicates impaired adipogenesis. *Diabetologia* 50:1707–1715
13. Cinti S, Mitchell G, Barbatelli G et al (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. *J Lipid Res* 46:2347–2355
14. Koenen TB, Tack CJ, Kroese JM et al (2009) Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients. *J Clin Endocrinol Metab* 94:4453–4457
15. Zhang HH, Huang J, Duvel K et al (2009) Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. *PLoS One* 4:e6189
16. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M (2013) Macrophage plasticity and polarization in tissue repair and remodelling. *J Pathol* 229:176–185
17. Bourlier V, Bouloumie A (2009) Role of macrophage tissue infiltration in obesity and insulin resistance. *Diabetes Metab* 35:251–260
18. Bernot D, Barriet E, Poggi M, Bonardo B, Alessi MC, Peiretti F (2010) Down-regulation of tissue inhibitor of metalloproteinase-3 (TIMP-3) expression is necessary for adipocyte differentiation. *J Biol Chem* 285:6508–6514
19. Chavey C, Mari B, Monthouel MN et al (2003) Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. *J Biol Chem* 278:11888–11896
20. Röss C, Tschoner A, Ciardi C et al (2010) Influence of significant weight loss on serum matrix metalloproteinase (MMP)-7 levels. *Eur Cytokine Netw* 21:65–70
21. Alligier M, Meugnier E, Debard C et al (2012) Subcutaneous adipose tissue remodeling during the initial phase of weight gain induced by overfeeding in humans. *J Clin Endocrinol Metab* 97:E183–E192
22. Kosteli A, Sugaru E, Haemmerle G et al (2010) Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. *J Clin Invest* 120:3466–3479
23. Koenen TB, Stienstra R, van Tits LJ et al (2011) The inflammasome and caspase-1 activation: a new mechanism underlying increased inflammatory activity in human visceral adipose tissue. *Endocrinology* 152:3769–3778
24. Bradley RL, Jeon JY, Liu FF, Maratos-Flier E (2008) Voluntary exercise improves insulin sensitivity and adipose tissue inflammation in diet-induced obese mice. *Am J Physiol Endocrinol Metab* 295:E586–E594
25. Enos RT, Davis JM, Velazquez KT et al (2013) Influence of dietary saturated fat content on adiposity, macrophage behavior, inflammation, and metabolism: composition matters. *J Lipid Res* 54:152–163